Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost-Reference-Cited by-同舟云学术

Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost

Published:2020-09 Issue:5 Volume:19 Page:584-588
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Ben Aicha Ibtihel,Hathout Lara,Carignan Damien^ORCID,Després Philippe,Lavallée Marie-Claude,Aubin Sylviane,Beaulieu Luc,Lacroix Frédéric,Foster William^ORCID,Martin André-Guy,Vigneault Eric

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference24 articles.

1. High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes;Vigneault;Radiother Oncol,2017

2. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer;Hoskin;Radiother Oncol,2012

3. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning;Hathout;Int J Radiat Oncol Biol Phys,2014

4. Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?;Steggerda;Radiother Oncol,2013

5. High dose rate prostate brachytherapy: An overview of the rationale, experience and emerging applications in the treatment of prostate cancer;Challapalli;Br J Radiol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of the bladder neck as an important organ at risk in prostate seed brachytherapy based on D2cc: A single-institution, retrospective review;Journal of Contemporary Brachytherapy;2023

2. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study;Brachytherapy;2021-11